Sirius Therapeutics has successfully secured nearly $50 million in Series B2 financing to accelerate the clinical development of its novel small interfering RNA (siRNA) therapeutics targeting cardiometabolic disorders. The funding will also support continued innovation of the company's next-generation RNA delivery technologies.
The financing round was led by an unnamed corporate venture capital firm and included participation from new investor BioTrack Capital, alongside existing investors OrbiMed, Creacion Ventures, and Hankang Capital.
"The successful completion of our Series B2 financing is a strong endorsement of our progress to date and our strategy going forward," said Dr. Qunsheng Ji, CEO of Sirius Therapeutics. "We are deeply grateful to our new and existing investors for their continued support. The funds from this round will further advance our clinical programs and expand our pipeline, to deliver transformative siRNA therapeutics for patients with chronic diseases around the world."
Advancing Clinical Pipeline
Sirius Therapeutics currently has three clinical-stage programs and a robust preclinical pipeline. The company's most advanced candidate, SRSD107, is a long-acting, next-generation anticoagulant designed for thromboembolic disorders. This program is now positioned to begin Phase 2 clinical development in Europe, with the company having recently submitted an application to the European Medicines Agency (EMA) to initiate the trial.
Additionally, Sirius has received regulatory approvals from both the U.S. Food and Drug Administration (FDA) and China's National Medical Products Administration (NMPA) for SRSD216, a novel siRNA therapeutic targeting hyperlipoproteinemia in patients with atherosclerotic cardiovascular disease. Phase 1 studies for this candidate have already commenced.
The company's third clinical program, SRSD101, is an siRNA therapeutic for dyslipidemia currently undergoing Phase 1 clinical trials in China.
siRNA Technology Platform
Sirius Therapeutics specializes in siRNA therapeutics, which work by silencing specific genes involved in disease processes. This approach offers potential advantages over traditional small molecule or antibody therapies, including longer duration of action and the ability to target previously "undruggable" disease pathways.
The company's focus on cardiometabolic disorders addresses significant unmet medical needs. Cardiovascular diseases remain the leading cause of death globally, while metabolic conditions such as dyslipidemia affect hundreds of millions of patients worldwide.
Company Growth and Global Presence
Founded in 2021, Sirius Therapeutics has established a dual-center operational model with an innovation center in the United States and a translational medicine center in China. This structure enables the company to leverage scientific expertise and clinical resources across both regions.
With this latest financing round, Sirius has raised approximately $150 million since its inception, demonstrating strong investor confidence in its scientific approach and business strategy. The company's rapid advancement of multiple candidates into clinical development within just three years of founding highlights its operational efficiency and the potential of its technology platform.
Market Context
The funding comes at a time of growing interest in RNA-based therapeutics, with several siRNA medications having received regulatory approval in recent years. The cardiometabolic space represents a particularly attractive target for siRNA approaches due to the chronic nature of these conditions and the need for treatments with improved efficacy and convenience.
As Sirius Therapeutics advances its lead candidates through clinical development, the company is positioned to potentially deliver novel treatment options for patients with cardiometabolic diseases who may benefit from the unique properties of siRNA therapeutics, including extended dosing intervals and targeted gene silencing.
